Optiscan has been featured in Stockhead in an article highlighting its mission to “ditch biopsies and bring pathology into the modern era.”

The story explores how Optiscan’s confocal laser endomicroscopy (CLE) is transforming cancer surgery and pathology, delivering real-time digital microscopic images “at a magnification 1000 times that of computed tomography (CT), or magnetic resonance imaging (MRI) scanning.”

CEO Dr. Camile Farah said, “Every field of medicine relies on pathology, one way or the other. Surgeons operate partly blind and critical decisions cannot be made on the spot.” Describing traditional biopsies as “the weakest link in clinical medicine today,” he added, “We have spent nearly 20 years validating and miniaturising the tech, to the degree the surgeon has a microscope in the palm of their hands.”

The article highlights Optiscan’s InVue device for precision-guided surgery, InForm for digital pathology, InSpecta for veterinary applications, and InVivage for oral cancer imaging — each part of a “device agnostic” platform that “fits into any endoscope.”

On the company’s telepathology collaboration with Prolucid Technologies, Dr. Farah described it as “Netflix for pathologists,” explaining, “In the same way as you stream movies, we can stream pathology images anywhere in the world, with no delay to the observable eye.”

Looking ahead, he said, “We believe Optiscan is the next great leap in medicine. No one in the world has this tech for these applications.”

Stockhead – Read the full article here.